Coalition to Cure Calpain 3 (C3) has recently awarded a research grant to Dr. Antoine Dufour. The project, titled ‘Unbiased Systems-wide Investigation of Calpain 3 in Patients with LGMD2A/R1 Using Mass Spectrometry,’ aims to better understand the biological role of
Dufour Lab to investigate the biological role of calpain 3 in muscle
Coalition to Cure Calpain 3 (C3) is celebrating the New Year with a new research grant! We are pleased to announce a grant has been awarded to Dr. Antoine Dufour, Assistant Professor of Physiology and Pharmacology at the University of
Plasmid-mediated Gene Therapy Shows Promise for LGMD2A/R1 Patients
PUBLISHED RESEARCH ALERT: Plasmid-Mediated Gene Therapy in Mouse Models of LGMD Coalition to Cure Calpain 3 (C3) is pleased to announce the publication of a new research paper from the group of Dr. Michele Calos, Stanford University School of Medicine.
2019 – The C3 Year In Numbers
2019 was a busy year for Coalition to Cure Calpain 3! During the past year we: • Funded two new research projects: Funding was awarded to Dr. Jaakko Sarparanta, Folkhälsan Research Center and the University of Helsinki, and Dr. Nicholas
Promising Insights into Safety of LGMD2A/R1 Gene Therapy Approach
Published research alert: Titin splicing regulates cardiotoxicity associated with Calpain-3 gene therapy for LGMD2A/R1 Coalition to Cure Calpain 3 (C3) is pleased to announce the publication of research undertaken by Dr. Isabelle Richard, Head of the Progressive Dystrophy Laboratory, Généthon,
Double your donation on Giving Tuesday 2019
A “C3 Champion” has made a commitment to match every dollar donated on Giving Tuesday, up to $25,000. Your contribution today to support scientific research for those families impacted by the muscle-wasting disease LGMD2A/R1 (a form of calpainopathy)
C3 Scientific Director Dr. Jennifer Levy Appointed to Muscular Dystrophy Coordinating Committee
The Muscular Dystrophy Coordinating Committee (MDCC) is a federal advisory committee that aims to coordinate the activities repeated to muscular dystrophy research across the National Institutes of Health (NIH) and other federal programs including the Centers for Disease Control and
2019 World Muscle Society Recap
The 24th International Annual Congress of the World Muscle Society was held October 1-5, 2019 in Copenhagen, Denmark. C3 Scientific Director Dr. Jennifer Levy represented Coalition to Cure Calpain 3 (C3) and presented a poster detailing the C3 mission, patient
An LGMD by any other name … is still an LGMD: New nomenclature for the LGMDs
Those who recently attended the National LGMD Conference in Chicago learned that the LGMDs are getting new names. In the old naming system, dominant LGMDs were called LGMD1s and recessive LGMDs were called LGMD2s. The subtypes were further delineated
New resource to learn about clinical research opportunities for LGMD2A
Are you or a family member with LGMD2A interested in participating in clinical research studies or trials? Click here to view C3’s new Clinical Research Opportunity Resource Center to learn more about clinical research and current opportunities to participate. This